Jean-Paul Kress: MorphoSys announced that it has entered into a business combination agreement to be acquired by Novartis

Jean-Paul Kress, CEO of MorphoSys, shared on LinkedIn:

“Last week, MorphoSys announced that it has entered into a business combination agreement to be acquired by Novartis. Throughout my over 20 years in the industry, I’ve spearheaded numerous M&A transactions, recognizing their pivotal role as a catalyst for innovation in medicine.

In 2021, MorphoSys acquired Constellation Pharmaceuticals with the aim of redefining how cancer is treated. Smaller companies can create tremendous value through acquisitions if they have the right expertise, skills and mindset to develop medicines. In 2023 – a little over two years later – we proved this. In record time, our team successfully demonstrated the clinical benefits of our investigational BET inhibitor, a potentially paradigm-shifting treatment option for people living with myelofibrosis. We focused our resources to ensure a successful trial, remaining agile, pragmatic and solutions-oriented along the way, and delivered positive results six months ahead of schedule. I am deeply appreciative of the hard work and unwavering dedication shown by every member of my team, and I take immense pride in all we have accomplished together.

Now we look to hand the reigns of our promising oncology pipeline over to Novartis, building on a decade-long development partnership. I am confident that Novartis’ global footprint and leadership in #oncology innovation will accelerate the speed and scale at which cancer patients’ significant needs are addressed.

These M&A opportunities remind us just how much we can accomplish for patients when we combine the right forces at the right time.

Read more and find important disclaimers here: https://bit.ly/491h7ZK”

Source: Jean-Paul Kress / LinkedIn